126 related articles for article (PubMed ID: 12533264)
1. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Bernard-Marty C; Treilleux I; Dumontet C; Cardoso F; Fellous A; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A
Clin Breast Cancer; 2002 Dec; 3(5):341-5. PubMed ID: 12533264
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
6. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
[TBL] [Abstract][Full Text] [Related]
7. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
9. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
11. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
12. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer.
Salminen E; Bergman M; Huhtala S; Jekunen A; Ekholm E
Anticancer Res; 2000; 20(5C):3663-8. PubMed ID: 11268436
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
[TBL] [Abstract][Full Text] [Related]
15. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
Chen X; Wu J; Lu H; Huang O; Shen K
Cancer Sci; 2012 Feb; 103(2):262-8. PubMed ID: 22035021
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Di Leo A; Chan S; Paesmans M; Friedrichs K; Pinter T; Cocquyt V; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Von Minckwitz G; Leroy JY; Durbecq V; Isola J; Aapro M; Piccart MJ; Larsimont D
Breast Cancer Res Treat; 2004 Aug; 86(3):197-206. PubMed ID: 15567936
[TBL] [Abstract][Full Text] [Related]
19. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
Parissenti AM; Chapman JA; Kahn HJ; Guo B; Han L; O'Brien P; Clemons MP; Jong R; Dent R; Fitzgerald B; Pritchard KI; Shepherd LE; Trudeau ME
Breast Cancer Res Treat; 2010 Jan; 119(2):347-56. PubMed ID: 19771508
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
